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to assess, from the governmental perspective, the cost-effectiveness of using QIV 
versus TIV as an influenza vaccination for children under 17 years old. Methods: 
A Markov model was used to assess the cost and effectiveness of QIV and TIV. Cost 
data were obtained from the National Health Insurance claims data. Vaccine effi-
cacy and transition probability of different health states were based on previous 
studies. Outcomes included cases avoided, life-years gained, QALYs gained and the 
corresponding incremental cost-effectiveness ratios (ICERs). The discount rate of 
cost and effectiveness was set at 3.5% and the time horizon used in the model is 100 
years. Results: The avoided influenza-associated outcomes form QIV, compared to 
TIV, and throughout the estimate lifetime were as follows: 251,512 influenza cases 
avoided, 32,355 cases with influenza complications avoided, 254,855 outpatient vis-
its avoided, 3,860 inpatients receiving treatment for complications avoided and 717 
deaths avoided. The ICER of this alternative, compared with TIV, was US$44,231.3 per 
QALY gained. When the herd effect was taken into consideration, the ICER dropped 
to US$30,947.85 per QALY gained. ConClusions: From the governmental perspec-
tive, the QIV of seasonal influenza is associated with favorable cost-effectiveness 
ratios in children under 17 years.
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A Cost MInIMIsAtIon AnAlysIs of GonAdotroPIns for In VItro 
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BAsed endPoInts In GerMAny
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objeCtives: The purpose of this analysis was to quantify the cost-effectiveness 
of recombinant follitropin alfa (r-hFSH) and highly purified urinary follicle stimu-
lating hormone (uFSH-HP) in the in-vitro fertilization (IVF) process. Methods: 
An Excel-based model estimated the drug cost per pregnancy and drug cost per 
live birth resulting from a hypothetical cohort of 1000 women undergoing IVF in 
Germany. Model inputs were taken from peer-reviewed published literature, and 
used to estimate the number of embryos generated per IU of gonadotropin used 
for ovarian stimulation. The cohort then underwent multiple rounds of embryo 
transfers (ETs) until embryo exhaustion or pregnancy as dictated by literature val-
ues. The obtained pregnancy rates were multiplied by the percentage of live births 
achieved per pregnancy according to the 2012 German IVF Registry to generate 
the live birth analysis. The cost inputs for r-hFSH and for uFSH-HP were ex-factory 
prices provided by Merck Serono affiliates in Germany. Cost inputs were limited to 
the cost of drug, as medical costs associated with the IVF procedure were assumed 
to be equal for both r-hFSH and uFSH-HP, and would not affect the comparison. 
All of the model outputs were age-agnostic and did not take into consideration 
procedural differences amongst fertility clinics, as the referenced clinical studies 
did not provide these details. Results: Treatment with r-hFSH resulted in a cost 
per pregnancy of 173€ (235USD, 10%) (Bergh et al.) and 47€ (64USD, 2%) (Frydman 
et al.) less than treatment with uFSH-HP. The cost per live birth was 622€ (846USD, 
15%) (Bergh et al.) and 312€ (424USD, 6%) (Frydman et al.) less with r-hFSH than for 
uFSH-HP. ConClusions: r-hFSH minimises the cost per pregnancy and cost per 
live birth in Germany. The results of the model demonstrate that r-hFSH represents 
a cost-effective gonadotropin to use for IVF ovarian stimulation.
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objeCtives: The objective of this analysis is to demonstrate the economic value of 
Duratocin® in the prevention of postpartum hemorrhage from uterine atony dur-
ing active management of the third stage of labour in elective caesarean section 
delivery. Methods: We analyzed the economic value of Duratocin® (carbetocin) in 
relation to the comparators most commonly encountered in clinical practice, and 
recommended in the clinical practice guidelines of the Society of Obstetricians and 
Gynecologists of Canada. We modeled the treatment pathways as described in the 
guidelines, and also the use of uterotonics encountered in typical Canadian practice, 
i.e. as a second-line intervention. Assuming that the ultimate incidence of postpar-
tum hemorrhage is equal between all treatment strategies, we constructed cost-
minimization models in TreeAge Pro (2013), with a time horizon of 8 hours. Transition 
probabilities were derived from the literature, and costs and resource consumption 
data were obtained from hospital databases and input from health care profession-
als. Results: Duratocin® was shown to be the lowest cost treatment strategy in the 
prevention of postpartum hemorrhage in elective caesarean section delivery using 
either guidelines or typical-use treatment pathways. The total expected cost of the 
carbetocin treatment strategy under the SOGC Guidelines scenario is $22.12, vs. $24.91 
for the oxytocin strategy. In the typical use scenario the results are even clearer, 
with carbetocin providing very substantial cost-savings compared to ergonovine or 
carboprost. ConClusions: These results were robust to all sensitivity analyses in 
the case of the typical-use scenario. In the SOGC Guidelines scenario the results were 
robust to all sensitivity analyses except the dosing of ergonovine.
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objeCtives: The purpose of this analysis was to quantify the cost-effectiveness of 
recombinant follitropin alfa (r-hFSH) and highly purified human menopausal gonado-
tropin (HP-hMG) in the in-vitro fertilization (IVF) process. Methods: An Excel-based 
model was constructed to estimate the cost per oocyte retrieved, cost per embryo gen-
erated, and cost per optimal chance of live birth for r-hFSH and HP-hMG in Sweden. 
Calgary and Saskatchewan HTS protocols were found to be costly compared to 
LTS with the Calgary protocol being the most costly. The Saskatchewan protocol 
was found to be less costly than the Calgary protocol primarily due to employing 
ultrasound as the initial confirmatory diagnostic which reduces the number of 
Hysterosalpingogram (HSG) procedures conducted compared to the Calgary proto-
col. However, while HTS is more costly than LTS, it was also more effective. The costs 
saved per successful procedure lost by switching from LTS to the Saskatchewan pro-
tocol or the Calgary protocol was $3,588 and $4,789, respectively. This result suggests 
that the Saskatchewan protocol is cost effective compared to the Calgary protocol 
(i.e. within HTS comparison) because the Saskatchewan protocol saves more money 
for a unit of effectiveness lost. ConClusions: The existing evidence suggest that 
compared to LTS, HTS is more costly but also more effective. While replacing eligible 
LTS procedures with HTS will result in costs decision makers will need to determine 
whether the amount of costs outweighs the amount of effectiveness gains.
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objeCtives: To perform a complete economic evaluation of cost-effectiveness on 
the use of Floseal versus standard treatment for obstetric haemorrhage in Mexican 
patients from the Public Health Sector point of view Methods: An economic analy-
sis was designed using data base from the UMAE 23 Hospital of Gynecology and 
Obstetrics ¨Dr. Ignacio Morones Prieto¨, to compare Floseal and Control (standard 
treatment) in obstetric haemorrhage. The efficiency measure was the percentage 
of patients who avoided surgical re-intervention. Only costs from medical attention 
were used such as: haemostatic agents, hospitalization and surgery. An incremental 
cost-effectiveness analysis was performed, as well as a (deterministic and stochas-
tic) sensitivity analysis, modifying cost and effectiveness of Floseal; and reinforced 
with the statistical analysis and lineal regression to determine de influence of sev-
eral parameters on the total cost. Results: The data base prove that Floseal is a 
more cost-effectiveness option than Control; 100% of patients avoided surgical re-
intervention compared to 46.66% of the Control (p< .0001). Patients that used Floseal 
had less hospitalization time and less time in the intensive care unit with respect 
to patients with standard treatment. And, Floseal in obstetric haemorrhage had 
an average cost per patient of $137,505, while Control group was $237,470 generat-
ing savings of $99,965 per patient. The sensitivity analysis, statistical analysis and 
lineal regression analysis proved the strength of these results. ConClusions: The 
economic evaluation proved that Floseal is an cost-effectiveness and safe option 
with respect to Control, used in obstetric haemorrhage in Mexican patients, hav-
ing a lesser cost while avoiding surgical re-interventions and hospitalization days.
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objeCtives: Prenatal distribution of misoprostol has been advocated as a strategy to 
increase access to uterotonics during the third stage of labor to prevent Post Partum 
Hemorrhage (PPH). The objective of this study was to project the potential cost-effec-
tiveness of this strategy in Uganda from both governmental (payer) and societal per-
spectives. Methods: To compare prenatal misoprostol distribution to the status quo 
(no misoprostol distribution), we developed a decision model that tracked the delivery 
pathways, outcomes and cost of a pregnant woman from the prenatal period to onset 
of labor, delivery without complications or delivery with PPH, and successful treat-
ment or death. Model parameters were derived from the Uganda Demographic and 
Health Survey and the published literature, as well as expert opinion. We computed 
expected probabilities of PPH and death due to PPH, Disability Adjusted Life Years 
(DALYs) and costs. In the incremental analysis, we calculated changes in expected 
probabilities of PPH and death due to PPH, Disability Adjusted Life Years (DALYs) and 
changes in costs. We conducted univariate and probabilistic sensitivity analyses to 
examine robustness of our results. Results: In the base case analysis, the expected 
probabilities of PPH and death due to PPH were lower with prenatal misoprostol dis-
tribution (14.0% versus 16.3% and 1.4% versus 1.7% respectively). Mean DALYs were 
lower with prenatal misoprostol distribution (0.408 versus 0.511). Mean costs were 
lower with prenatal misoprostol distribution both from the governmental ($17.42 
versus $18.27) and societal ($30.02 versus $31.55) perspectives. In the incremental 
analysis, prenatal misoprostol distribution was a dominant strategy i.e. it was both 
less costly and more effective. This result was robust to univariate and probabilistic 
sensitivity analysis. ConClusions: Prenatal distribution of misoprostol is poten-
tially cost-effective in Uganda. It would potentially save lives and money and should 
be considered for national-level scale up for prevention of PPH.
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Cost-effeCtIVeness of QuAdrIVAlent Versus trIVAlent InfluenzA 
VACCInes for CHIldren
Yang M.C., Tan C.H.
National Taiwan University, Taipei, Taiwan
objeCtives: Influenza could cause serious consequences, especially on children. 
The WHO recommended that influenza vaccination of children is the most effective 
means. Trivalent influenza vaccine (TIV), which contains two lineages of influenza 
A virus and one lineage of influenza B virus, is now use as a first-line strategy to 
prevent influenza in Taiwan. However, when the influenza B-lineage included in the 
TIV mismatched with circulating strains, the protection of TIV would be reduced. 
Quadrivalent influenza vaccine (QIV) which includes both influenza B viruses of the 
two circulating lineages is thus proposed as an alternative. The aim of the study was 
A162  VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 1 - A 2 9 5  
objeCtives: Despite the clear benefits of high adherence, interventions aimed at 
improving adherence have had mixed success. This study reviewed the evidence 
associated with the following adherence intervention types: functional (e.g., intro-
ducing medication reminder systems), educational interventions (e.g., improving 
disease and adherence education), and motivational interventions (e.g., improving 
social support; incentivizing/reducing barriers to adherence). Methods: A prior 
systematic literature review on adherence interventions conducted by the Agency 
for Healthcare Research and Quality was updated focusing on interventions which 
had functional (e.g., making it easier for patients to remember medications), edu-
cational (e.g., increasing disease or adherence knowledge), or motivational (e.g., 
reducing financial barriers) components published up until November 2013. A total 
of 78 articles were reviewed. Results: Functional interventions were the most 
common (63.3% of all the studies) and about two-thirds of the interventions were 
significant. The effects of educational interventions (appearing in 32.9% of studies) 
were small; approximately half of interventions showed an effect, though the non-
significant interventions had smaller sample sizes (n= 150 or less). Motivational 
interventions (10.1% of all studies) were the most consistent in their effects (all 
but one study reported a significant finding) but were modest with only a 2-6% 
increase in adherence rates. Multifaceted interventions, which most often com-
bined functional and education components, appeared in 15.2% of studies. These 
interventions had the largest effect size with a third reporting at least 20% increases 
in adherence rates relative to controls. ConClusions: The results reinforce the 
challenge with improving adherence among patients with chronic disease. Although 
it is difficult to draw firm conclusions based on the heterogeneous interventions, 
functional interventions produced the largest changes in adherence. Motivational 
interventions, particularly when they are financial, had the most consistent effects, 
albeit small ones. However, multi-faceted interventions (combining functional and 
education interventions) were the most successful of all.
PIH48
A QuAlItAtIVe exPlorAtIon of stI sCreenInG PrACtICes And BArrIers 
AMonG oBGyns And fAMIly PrACtItIoners In tHe unIted stAtes
Mehringer M.1, Hertz D.2, DiPaolo A.2
1Hologic Gen-Probe, San Diego, CA, USA, 2GfK Market Access, Wayland, MA, USA
objeCtives: Despite consistent sexually transmitted infection (STI) screening 
guidelines for asymptomatic women, less than half of women age 25 and younger 
are being tested for chlamydia trachomatis (CT) and neisseria gonorrhea (NG). This 
study sought to understand how physicians determine which patients to screen 
and the perceived barriers to screening. Methods: Sixty semi-structured, 45-min 
phone interviews were conducted from a nationally representative sample of 30 
Obstetric-Gynecologists (OBGyns) and 30 Family Practitioners (FPs). Respondents 
were recruited if they had 5-30 years of experience and reported that they some-
time, often or always perform STI testing. A thematic approach was used to analyze 
the data. Results: Approximately 1 in 4 FPs offer STI testing only to sympto-
matic patients. OBGyns were more likely to screen based solely on age. However, 
approximately half of all interviewees used age in conjunction with a clinical risk 
assessment to determine which patients to offer screening. The most frequently 
sited barriers to screening for STIs were: Patients not wanting the tests, Patients 
not seeking regular care, Parents or partners present in the room, Patient anxiety/
embarrassment, and Patient cost concerns. The majority of respondents (75%) felt 
lab algorithms that automated the STI testing based on screening criteria would be 
helpful. ConClusions: Most physicians selectively offer STI screening to women 
based on age and a risk assessment, with patients opting-in by specifically saying 
they want STI screening. The adopting of automated STI testing with an opt-out 
option for women age 15-25 would help reduce inconsistencies in physician’s test 
ordering, align practice with clinical guidelines, reduce stigma associated with STI 
testing, and increase the rate of patient acceptance by overcoming some of the 
barriers to screening.
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A systeMAtIC reVIew of tHe effeCtIVeness of HeAltH InforMAtIon 
teCHnoloGy InterVentIons In IMProVInG MedICAtIon AdHerenCe
Nigam S., Mitra D., Lahue B.J.
Becton Dickinson, Franklin Lakes, NJ, USA
objeCtives: To evaluate the effectiveness of health information technology (HIT) 
interventions in improving medication adherence. Methods: We conducted a 
systematic review of English language articles that employed health information 
technology (HIT) interventions to improve medication adherence in the United 
States from January 1st 2008 and December 31st2013 in peer-reviewed journals using 
PubMed. Our search was unrestricted by study design or disease area. PubMed Search 
Strategy: ((“Telemetry/instrumentation”[Mesh]) OR (“Technology”[MeSH Terms]) 
OR (“Medical Informatics Applications”[MeSH Terms]) OR (“Telemedicine”[MeSH 
Terms])) AND (“Medication Adherence”[MeSH Terms]) AND (“United States”[MeSH 
Terms]). Results: 102 studies were identified and 19 were included in our review. 
Studies were excluded if they did not employ an HIT intervention for improving 
medication adherence and were instead focused on monitoring or measurement of 
medication adherence. The included studies spanned various disease states such 
mental health, diabetes, asthma, hypertension, depression, cardiovascular disease 
and HIV/AIDS. We found that the most commonly studied HIT interventions include 
SMS/text messaging, telemonitoring, and electronic prescribing. Overall, we found 
limited data regarding the effectiveness of HIT interventions in improving medica-
tion adherence. However, interventions such as telemonitoring were found to be 
effective in diseases such as asthma and diabetes, while text messaging appears to 
be promising in HIV/AIDS and diabetes. We posit that the rapidly evolving nature of 
the HIT field may be a challenge in performing rigorous outcomes studies to meas-
ure endpoints such as medication adherence. But larger trials with adequate sta-
tistical power are needed so that findings are more generalizable. ConClusions: 
Comparative effectiveness and outcomes research is a key tool to inform policy, 
provider and patient decision-making and we recommend additional research on 
Model inputs were taken from the literature. The cost inputs for r-hFSH and its urinary 
competitors were ex-factory prices provided by Merck Serono affiliates in Sweden. 
Cost inputs were limited to the cost of gonadotropin, as medical costs were assumed 
to be equal for r-hFSH and its competitors and would not affect the comparison. To 
estimate the cost per oocyte produced or embryo generated, the prices of r-hFSH and 
of HP-hMG were multiplied by the average dose of gonadotropin and divided by the 
average number of oocytes or embryos produced according to published studies.To 
estimate the cost per optimal chance of live birth, the cost to produce 15 oocytes was 
calculated. Prior studies have demonstrated that the production of 15 oocytes leads to 
the greatest probability of obtaining a live birth. The model outputs were age-agnostic 
and did not take into consideration procedural differences amongst fertility clinics, as 
the referenced clinical studies did not provide these details. Results: The cost per 
oocyte retrieved, cost per embryo generated and cost per optimal chance of live birth 
were each 17% less when comparing r-hFSH to HP-hMG. ConClusions: r-hFSH is 
cost-minimising relative to HP-hMG from the perspective of cost per oocyte retrieved, 
cost per embryo generated, and cost per optimal chance of live birth. The analysis 
demonstrates the importance of considering outcomes while comparing costs, as 
the ‘cost per vial’ in isolation may be a misleading determinant of cost-effectiveness.
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objeCtives: Rotavirus vaccination is reimbursed in Belgium since 2006 with an 
initial vaccine uptake in the target group > 85%. Cost-effectiveness analysis of the 
vaccine is presented with indirect cost gained based on the reduction of loss in pro-
ductivity. Seven years later we are able to estimate this important parameter with 
real-world data. Methods: The City of Antwerp collects data on absence from work 
of its administrative employees: reason, duration, time period (n ~ 10,000 women). 
We analysed the data retrospectively from 2003 to 2012, comparing the absence 
duration amongst mothers with a first child before and after vaccine introduction. 
We assumed that rotavirus infection related absenteeism was mostly seen during 
the epidemic period -from January to May- and involved short-duration absences 
(≤ 5 days). We reported the analysis overall by annual birth cohort followed over 3 
years (being the risk exposure period). Finally we compared the data from June to 
December (i.e. outside the epidemic period) expecting no change in short-duration 
absenteeism overtime. Results: 2.24% of the working women are getting a first 
child each year (224 women). Without vaccination they spent on average 1,056 accu-
mulated days of short-duration absence (4.7 days per mother spread over 3 years) 
during the epidemic period. Since the introduction of the vaccine, that number was 
reduced to 499 days (47% decrease). The difference between the epidemic and the 
non-epidemic periods per year was 192 days before the introduction of the vaccine 
and it was reduced to 18 days thereafter. ConClusions: A reduction in absentee-
ism amongst working mothers with a first child of the administrative personnel 
of the City of Antwerp is observed since the introduction of rotavirus vaccine. This 
reduction can be substantial, estimated at 2.2 days gained per person on average.
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deterMInInG tHe BenefIts of ProACtIVe dIGItAl serVICe for CoMPuted 
toMoGrAPHy (Ct) sCAnners
Bonnet P.O., Roy A., Peyronnet J.M.
GE Healthcare, Wauwatosa, WI, USA
objeCtives: CT users are concerned about operational disruptions and aim at 
reducing the number of emergency requests for service. The objective of this 
study was to determine if proactive monitoring can help reduce unplanned down-
time. Methods: CT systems monitored using the OnWatch technology were 
included in the analysis. Data was collected between 2011 and 2013 to allow com-
parison before and after activation. Service events such as number of disruptions, 
average disruption duration, and average downtime per system were compared 
between the pre-OnWatch and post-OnWatch periods. Service events occurring 
within the 2-week period following OnWatch installation were excluded as the acti-
vation triggers an unusual number of events and could skew the results. Results: 
136 CT systems and 3045 service events were analyzed. Though the overall number 
of service events increased by 19% after OnWatch activation, the average number of 
disruptive events (emergency customer calls) per month decreased by 13%, from 0.76 
to 0.66 (p= .02). The mean duration of emergency calls was reduced by 21%, from 11.7 
to 9.2 hours (p= .02). 89 out of 140 the systems (63.6%) showed an improvement in 
downtime. Average downtime per month for emergency calls was reduced by 32%, 
from 7.97 to 5.42 hours, after the adoption of OnWatch (p< .001). Using a conservative 
range of two to four procedures per hour and an average payment rate of $400, 2.55 
hours of increased system availability per month could represent between $24,480 
and $48,960 of potential additional revenue per system. ConClusions: CT users 
value the ability of service to reduce the number of emergency events as operational 
disruptions and lost revenue due to downtime are genuine concerns. The results of 
this analysis suggest that OnWatch allows CT users to maintain workflow efficiency 
by turning unplanned downtime into more predictable service events.
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